Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen.

Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatinbased regimen / Vignani F; Russo L; Tucci M; Motta M; Vellani G; Tampellini M; Papotti M; Dogliotti L; Berruti A.. In: ANNALS OF ONCOLOGY. ISSN 0923-7534. 20:12(2009), pp. 2019-2020. Original Citation: Why castration-resistant prostate cancer patients with neuroendocrine differentiation should be addressed to a cisplatin-based regimen

[1]  B. Escudier,et al.  Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  M. Papotti,et al.  Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. , 2007, The Journal of urology.

[3]  P. Thall,et al.  Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  P. A. Sant'agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  P. di Sant'Agnese,et al.  Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  T. H. van der Kwast,et al.  Kinetics of neuroendocrine differentiation in an androgen-dependent human prostate xenograft model. , 1999, The American journal of pathology.